Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.
Shares Monte Rosa Therapeutics shares were higher after the company reported positive interim data from a Phase 1/2 trial for a prostate cancer treatment. Shares were up 9.4% to $18.00 in Tuesday ...
In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback